Attenuated FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second -line chemotherapy for the Koreans (Asian population) with gemcitabineresistant or -refractory advanced pancreatic cancer.

被引：0
|
作者：
Lee, Sang-Cheol
Kim, Jung Hoon
Oh, Sung Yong
Kim, Kyoungha
Song, Seo-Young
Lee, Namsu
Nam, Eun M. I.
Lee, Soonil
Hwang, In Gyu
Lee, Hyo Rak
Won, jong-Ho
Lee, Kyu Taek
Bae, Sang-Byung
Kim, Hanjo
Kim, Hyun Jung
Jang, JoungSoon
Lim, Do Hyoung
Lee, Hyun Woo
Kang, Jung Hun
机构：
[1] Soonchunhyang Univ Hosp Seoul, Coll Med, Dept Internal Med,Div Hematol Oncol, Seoul, South Korea
[2] Hallym Univ, Chuncheon Sacred Heart Hosp, Div Hematol Oncol, Dept Internal Med, Chunchon, South Korea
[3] Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea
[4] Soonchunhyang Univ Hosp Seoul, Seoul, South Korea
[5] Kangwon Natl Univ Hosp, Sch Med, Dept Internal Med, Chunchon, South Korea
[6] Ewha Womans Univ, Seoul, South Korea
[7] Dankook Univ Hosp, Coll Med, Dept Internal Med, Cheonan, South Korea
[8] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[9] Korea Canc Ctr Hosp, Dept Internal Med, Seoul, South Korea
[10] Soonchunhyang Univ, Cheonan Hosp, Cheonan, South Korea
[11] Soonchunhyang Univ Hosp Cheonan, Cheonan, South Korea
[12] Soonchunhayng Univ, Coll Med, Bucheon Hosp, Bucheon, South Korea
[13] Chung Ang Univ Hosp, Seoul, South Korea
[14] Dankook Univ Hosp, Cheonan, South Korea
[15] Ajou Univ Hosp, Suwon, South Korea
[16] Gyeongsang Natl Univ Hosp, Sch Med, Div Hematol Oncol, Dept Internal Med, Jinju, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15731
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15731
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer
    Boukovinas, I.
    Androulakis, N.
    Polyzos, A.
    Vardakis, N.
    Amarantidis, K.
    Bozionelou, V.
    Kouroussis, C.
    Giassas, S.
    Christophyllakis, C.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Patterns of use and outcomes with irinotecan and oxaliplatin in the treatment of 5-fluorouracil (5-FU) refractory metastatic colorectal cancer: An Australian population based analysis.
    Damianovich, D.
    Adena, M.
    Tebbutt, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 178S - 178S
  • [33] A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy
    Grierson, Patrick
    Wang-Gillam, Andrea
    Park, Haeseong
    Pedersen, Katrina
    Tan, Benjamin R.
    Amin, Manik A.
    Suresh, Rama
    Trikalinos, Nikolaos
    Liu, Jingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
    Grierson, Patrick M.
    Suresh, Rama
    Tan, Benjamin
    Pedersen, Katrina S.
    Amin, Manik
    Park, Haeseong
    Trikalinos, Nikolaos A.
    Liu, Jingxia
    Boice, Nicholas
    Brown, Amberly
    Bansod, Sapana
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    CLINICAL CANCER RESEARCH, 2023, 29 (23) : 4733 - 4739
  • [35] Phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU based chemotherapy.
    Schöffski, P
    Harstrick, A
    Kirchner, H
    Trenn, G
    Bokemeyer, C
    Preusser, P
    Achterrath, W
    Deub, B
    Wilke, H
    ANNALS OF ONCOLOGY, 2000, 11 : 44 - 44
  • [36] Overall survival (OS) of patients with advanced gastric cancer (AGC) according to the availability of 5-FU, platinum, taxanes and irinotecan as first, second and third-line chemotherapy
    Kim, M. J.
    Yoo, K. H.
    Lee, S. J.
    Kim, S.
    Lee, J.
    Park, S. H.
    ANNALS OF ONCOLOGY, 2015, 26
  • [37] A phase II study of weekly oxaliplatin and high dose 5-FU with LCV as second line therapy in patients with advanced colorectal cancer
    Janinis, J
    Fountzilas, G
    Papakostas, P
    Efstathiou, E
    Valagouti, D
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 44
  • [38] Prognostic value of ERCC1, thymidylate synthase and glutathione S-transferase π for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kwon, H.
    Roh, M. S.
    Oh, S. Y.
    Kim, S.
    Lee, J. H.
    Kim, J.
    Park, J. I.
    Park, K. J.
    Choi, H. J.
    Kim, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 172S - 172S
  • [39] A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy
    Grierson, Patrick
    Suresh, Rama
    Tan, Benjamin R.
    Pedersen, Katrina Sophia
    Amin, Manik A.
    Park, Haeseong
    Trikalinos, Nikolaos
    Liu, Jingxia
    Lim, Kian-Huat
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] Combination of oxaliplatin (OXA) and 5-fluorouracil, leucovorin (5-FU/LV), as first line therapy, in elderly patients >70years, with metastatic colorectal cancer.
    Botto, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 298S - 298S
12345